Brookline initiates Revolution Medicines stock with buy rating
Brookline Capital Markets initiated coverage on Revolution Medicines (NASDAQ:RVMD) with a buy rating and a $318 price target. The stock is up 367% over the past year. Brookline estimates revenue growing from $151M in 2026 to $59.5B in 2033, with positive cash flow expected in 2027. The company recently launched Rasonque for pancreatic cancer, with FDA approval based on improved survival rates.
How this was made
The 30-second read
Why it matters
The coverage could attract new capital and lift the stock, but valuation concerns remain.
Market read
New buy rating and price target provide a fresh catalyst for RVMD, likely prompting short‑term buying interest.
What to watch
Potential reimbursement challenges and competition from other RAS inhibitors.
Background
The article announces new analyst coverage and price target for Revolution Medicines following its FDA approval.
Ticker impact
Brookline Capital Markets initiated coverage on Revolution Medicines with a buy rating and a $318 price target, citing recent FDA approval of Rasonque.
upward pressure as investors price in the new buy rating and FDA approval.
Buy rating and $318 target are substantially above current price, indicating expected price appreciation.
Market effects
Positive signal for the RAS‑targeted oncology biotech niche.
U.S. biotech sector may see modest uplift.
Limited to investors tracking late‑stage oncology pipelines.
Counterpoint
The high valuation may be premature given cash burn and debt levels.
Key entities
- AnalystBrookline Capital Markets
Initiated coverage with a buy rating and $318 price target.
- CompanyRevolution Medicines Inc.
Biotech firm with FDA‑approved RAS inhibitor Rasonque.
